KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Gross Margin (2021 - 2025)

Novavax has reported Gross Margin over the past 10 years, most recently at 84.98% for Q4 2025.

  • Quarterly results put Gross Margin at 84.98% for Q4 2025, up 2650.0% from a year ago — trailing twelve months through Dec 2025 was 93.1% (up 2282.0% YoY), and the annual figure for FY2025 was 93.5%, up 2322.0%.
  • Gross Margin for Q4 2025 was 84.98% at Novavax, up from 69.49% in the prior quarter.
  • Over the last five years, Gross Margin for NVAX hit a ceiling of 100.0% in Q1 2021 and a floor of 45.8% in Q2 2022.
  • Median Gross Margin over the past 5 years was 77.23% (2025), compared with a mean of 66.84%.
  • Biggest five-year swings in Gross Margin: crashed -14580bps in 2022 and later skyrocketed 13266bps in 2023.
  • Novavax's Gross Margin stood at 100.0% in 2021, then plummeted by -51bps to 49.14% in 2022, then fell by -5bps to 46.81% in 2023, then grew by 25bps to 58.48% in 2024, then surged by 45bps to 84.98% in 2025.
  • The last three reported values for Gross Margin were 84.98% (Q4 2025), 69.49% (Q3 2025), and 91.24% (Q2 2025) per Business Quant data.